AFM28, a Novel Bispecific Innate Cell Engager (ICE ®), Designed to Selectively Re-Direct NK Cell Lysis to CD123+Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome

被引：3
|
作者：
Goetz, Jana-Julia [1 ]
Pahl, Jens [1 ]
Schmitt, Nanni [2 ]
Mueller, Thomas [1 ]
Haneke, Torsten [1 ]
Kozlowska, Izabela [1 ]
Sarlang, Séverine [1 ]
Knackmuss, Stefan [1 ]
Peters, Eike [1 ]
Reusch, Uwe [1 ]
Ross, Thorsten [1 ]
Nowak, Daniel [2 ]
Hofmann, Wolf-Karsten [2 ]
Merz, Christian [1 ]
机构：
[1] Affimed GmbH, Heidelberg, Germany
[2] Heidelberg Univ, Univ Hosp Mannheim, Mannheim, Germany
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152463
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3344
引用
收藏
页数：4
相关论文
共 14 条
  • [1] Novel bispecific innate cell engager AFM28 efficiently directs allogenic NK cells to CD123+leukemic blasts and stem cells in acute myeloid leukemia and myelodysplastic neoplasms
    Schmitt, N.
    Siegler, J. -J
    Pahl, J.
    Wagner, L.
    Schulze, N.
    Beck, A.
    Haneke, T.
    Reusch, U.
    Medina-Echeverz, J.
    Endell, J.
    Hofmann, W-K
    Ross, T.
    Nowak, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 100 - 101
  • [2] The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+Leukemic Stem- and Progenitor Cells in AML
    Schmitt, Nanni
    Siegler, Jana-Julia
    Wagner, Lena
    Schulze, Nicole
    Beck, Alexandra
    Hofmann, Wolf-Karsten
    Haneke, Torsten
    Reusch, Uwe
    Medina-Echeverz, Jose
    Endell, Jan
    Ross, Thorsten
    Merz, Christian
    Nowak, Daniel
    BLOOD, 2022, 140 : 8815 - 8816
  • [3] PRE-CLINICAL MODELS OF ACUTE MYELOID LEUKEMIA DEMONSTRATE AFM28 EFFICIENTLY DIRECTS ALLOGENEIC NK CELLS TO CD123+LEUKEMIC BLASTS AND STEM CELLS
    Siegler, Jana-Julia
    Schmitt, Nanni
    Wagner, Lena
    Schulze, Nicole
    Beck, Alexandra
    Hofmann, Wolf-Karsten
    Haneke, Torsten
    Reusch, Uwe
    Medina-Echeverz, Jose
    Ross, Thorsten
    Merz, Christian
    Nowak, Daniel
    Endell, Jan
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 120 - 121
  • [4] Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study
    Montesinos, Pau
    Arnan, Montserrat
    De Botton, Stephane
    Calbacho, Maria
    Veiga, Rebeca Rodriguez
    Bories, Pierre
    Ansoleaga, Belen
    Hueso, Thomas
    Daver, Naval
    Wunderle, Lydia
    Harstrick, Andreas
    Pietzko, Kerstin
    Hajela, Pallavi
    Vasile, Alexandra
    Witte, Tania
    Saenger, Elmarie
    Recher, Christian
    BLOOD, 2024, 144 : 739 - 739
  • [5] The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient's NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CDI23+Leukemic Stem and Progenitor Cells in AML and MDS
    Schmitt, Nanni
    Siegler, Jana-Julia
    Beck, Alexandra
    Hoppe, Lea
    Abba, Mohammed
    Streuer, Alexander
    Klein, Stefan
    Hofmann, Wolf-Karsten
    Merz, Christian
    Pahl, Jens
    Nowak, Daniel
    BLOOD, 2024, 144 : 4143 - 4143
  • [6] AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies.
    Pahl, Jens
    Hintzen, Gabriele
    Reusch, Uwe
    Haneke, Torsten
    Breunig, Christian
    Pinto, Sheena
    Choe-Juliak, Cassandra
    Harstrick, Andreas
    Fischer, Wolfgang
    Schottelius, Arndt
    Koch, Joachim
    Rajkovic, Erich
    CANCER RESEARCH, 2021, 81 (13)
  • [7] A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
    Arruda, Lucas C. M.
    Stikvoort, Arwen
    Lambert, Melanie
    Jin, Liqing
    Rivera, Laura Sanchez
    Alves, Renato M. P.
    de Moura, Tales Rocha
    Mim, Carsten
    Lehmann, Soren
    Axelsson-Robertson, Rebecca
    Dick, John E.
    Mattsson, Jonas
    Onfelt, Bjorn
    Carlsten, Mattias
    Uhlin, Michael
    HAEMATOLOGICA, 2022, 107 (08) : 1786 - 1795
  • [8] Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies
    Reusch, Uwe
    Ellwanger, Kristina
    Fucek, Ivica
    Mueller, Thomas
    Schniegler-Mattox, Ute
    Pahl, Jens
    Tesar, Michael
    Koch, Joachim
    BLOOD, 2021, 138
  • [9] An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.
    Boissel, Nicolas
    de Botton, Stephane
    Thomas, Xavier G.
    Rao, Ercole
    Bonnevaux, Helene
    Rubin-Carrez, Chantal
    Guerif, Stephane
    Beys, Eric
    Gosselin, Alice
    Bauchet, Anne-Laure
    Novikov, Valery
    Fernandes, Elma
    Wiederschain, Dmitri
    Palatinsky, Emanuel A.
    Hsu, Karl
    Fraenkel, Paula Goodman
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] A Novel CD16xCD33 Bispecific Killer Cell Engager (BiKE) Mediates a Double Hit For Natural Killer (NK) Cells To Target CD33+ Myelodysplastic Syndrome (MDS) Cells and Myeloid Derived Suppressor Cells (MDSCs) At All Disease Stages
    Gleason, Michelle K.
    Ross, Julie A.
    Lund, Troy C.
    Verneris, Michael R.
    Wiernik, Andres
    Warlick, Erica D.
    Spellman, Stephen
    Haagenson, Michael D.
    Lenvik, Alexander J.
    Litzow, Mark R.
    Weisdorf, Daniel J.
    Vallera, Daniel A.
    Miller, Jeffrey S.
    BLOOD, 2013, 122 (21)
12